UBS upgraded Oscar Health, Inc. (NYSE:OSCR) to Neutral and raised price target to $17, citing strong exchange enrollment trends. In Q3 2025, OSCR reported a 23% increase in total revenue to $3.0 billion, with plans to expand into 20 states for 2026. OSCR, founded in 2012, focuses on digital tools and data-driven plan design for health insurance.

Read more at Yahoo Finance: Oscar Health, Inc. (OSCR) Upgraded as Valuation Appears Balanced